2025/03/20 更新

写真a

ワタナベ ユキヒロ
渡邉 将央
Watanabe Yukihiro
所属
付属病院 心臓血管集中治療科 助教
職名
助教

研究キーワード

  • 構造的心疾患

  • 虚血性心疾患

  • 心筋症

  • 心不全

研究分野

  • ライフサイエンス / 循環器内科学

学歴

  • 日本医科大学 医学部 医学科

    2010年4月 - 2017年3月

      詳細を見る

  • 日本医科大学 大学院医学研究科 機能形態解析医学領域 循環器内科学

    2022年4月

      詳細を見る

経歴

  • 日本医科大学付属病院   心臓血管集中治療科   助教

    2025年1月 - 現在

      詳細を見る

  • 日本医科大学付属病院   循環器内科   助教

    2022年4月 - 2024年12月

      詳細を見る

  • 博慈会記念総合病院   循環器科

    2021年10月 - 2022年3月

      詳細を見る

  • 日本医科大学付属病院   循環器内科

    2020年10月 - 2021年9月

      詳細を見る

  • 日本医科大学多摩永山病院   循環器内科

    2020年4月 - 2020年9月

      詳細を見る

  • 日本医科大学付属病院   循環器内科

    2019年4月 - 2020年3月

      詳細を見る

  • NTT東日本関東病院

    2017年4月 - 2019年3月

      詳細を見る

▼全件表示

所属学協会

  • 日本心臓病学会

      詳細を見る

  • 日本アミロイドーシス学会

      詳細を見る

  • 日本心血管インターベンション治療学会

      詳細を見る

  • 日本内科学会

      詳細を見る

  • 日本循環器学会

      詳細を見る

  • 日本心不全学会

      詳細を見る

  • 日本心臓リハビリテーション学会

      詳細を見る

  • 日本経カテーテル心臓弁治療学会

      詳細を見る

▼全件表示

論文

  • Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights from the Tokyo Cardiovascular Care Unit Network Registry 査読

    Yukihiro Watanabe, Tsutomu Yoshikawa, Kenshiro Arao, Toshiaki Isogai, Tetsuo Yamaguchi, Toru Egashira, Yoichi Imori, Hiroki Mochizuki, Takeshi Yamamoto, Kuniya Asai, Shun Kohsaka, Morimasa Takayama

    The American Journal of Cardiology   2025年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.amjcard.2024.11.022

    researchmap

  • Temporal Changes in HbA1c Levels after Sacubitril/Valsartan Initiation in a Real-world Japanese Cohort: REVIEW-HF Registry 査読

    Yukihiro Watanabe, Yoshiaki Kubota, Takuya Nishino, Takahito Nasu, Shunsuke Ishii, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Koshiro Kanaoka, Shingo Matsumoto

    JMA Journal   8 ( 1 )   281 - 285   2025年1月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japan Medical Association  

    DOI: 10.31662/jmaj.2024-0242

    researchmap

  • Impact of polypharmacy on 3-year mortality in patients with heart failure: a retrospective study. 国際誌

    Daisuke Hayashi, Yoshiaki Kubota, Takuya Nishino, Yukihiro Watanabe, Yoshiki Iwade, Junya Matsuda, Katsuhito Kato, Shuhei Tara, Yuya Ise, Yu-Ki Iwasaki, Kuniya Asai

    Journal of pharmaceutical health care and sciences   10 ( 1 )   34 - 34   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Guideline-directed medical therapy (GDMT) is important in heart failure management; however, polypharmacy itself may impact heart failure. Although measures against polypharmacy are needed, current discussion on unilateral drug tapering (including the drugs that should be tapered) is insufficient. In this study, we investigated the relationship between the number of prescribed GDMT drugs and prognosis in patients with heart failure. METHODS: In this single-centre retrospective study, 3,146 eligible patients with heart failure were included and divided into four groups based on the median number of prescribed GDMT drugs and the median number of drugs not included in the GDMT (ni-GDMT) at the time of hospital discharge. The definition of GDMT was based on various Japanese guidelines. The primary outcome was all-cause mortality within 3 years of hospital discharge. RESULTS: A total of 252 deaths were observed during the 3-year follow-up period. Kaplan-Meier analysis revealed that groups with GDMT drug count ≥ 5 and ni-GDMT drug count < 4 had the lowest mortality, and those with GDMT drug count < 5 and ni-GDMT drug count ≥ 4 had the highest mortality (log-rank, P < 0.001). Cox regression analysis revealed a significant association between ni-GDMT drug count and all-cause mortality, even after adjustment for number of GDMT medications, age, male, left ventricular ejection function < 40%, hemoglobin, albumin levels, and estimated glomerular filtration rate [HR = 1.06 (95% CI: 1.01-1.11), P = 0.020]. Conversely, the GDMT drug count was not associated with increased mortality rates. CONCLUSIONS: The ni-GDMT drug count was significantly associated with 3-year mortality in patients with heart failure. Conversely, the GDMT drug count did not worsen the prognosis. Polypharmacy measures should consider ni-GDMT drug quantity to improve the prognosis and outcomes in patients with heart failure.

    DOI: 10.1186/s40780-024-00357-7

    PubMed

    researchmap

  • Reinforcement of pimobendan with guideline-directed medical therapy may reduce the rehospitalization rates in patients with heart failure: retrospective cohort study. 国際誌

    Yoshiki Iwade, Yoshiaki Kubota, Daisuke Hayashi, Takuya Nishino, Yukihiro Watanabe, Katsuhito Kato, Shuhei Tara, Yuya Ise, Kuniya Asai

    Journal of pharmaceutical health care and sciences   10 ( 1 )   24 - 24   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pimobendan reportedly improves the subjective symptoms of heart failure. However, evidence of improved prognosis is lacking. This study aimed to determine whether reinforcing guideline-directed medical therapy (GDMT) improved rehospitalization rates for worsening heart failure in patients administered pimobendan. METHODS: A total of 175 patients with heart failure who were urgently admitted to our hospital for worsening heart failure and who received pimobendan between January 2015 and February 2022 were included. Of the 175 patients, 44 were excluded because of in-hospital death at the time of pimobendan induction. The remaining 131 patients were divided into two groups, the reduced ejection fraction (rEF) (n = 93) and non-rEF (n = 38) groups, and further divided into the GDMT-reinforced and non-reinforced groups. RESULTS: In patients with rEF, the rate of rehospitalization for heart failure was significantly lower in the GDMT-reinforced group than in the non-reinforced group (log-rank test, P = .04). However, the same trend was not observed in the non-rEF group. CONCLUSIONS: Reinforcing GDMT may reduce the heart failure rehospitalization rate in patients with pimobendan administration and rEF. However, multicenter collaborative research is needed. TRIAL REGISTRATION: IRB Approval by the Nippon Medical School Hospital Ethics Committee B-2021-433 (April 10, 2023).

    DOI: 10.1186/s40780-024-00346-w

    PubMed

    researchmap

  • Impact of Red Blood Cell Transfusion on Subsequent Cardiovascular Events in Patients with Acute Heart Failure and Anemia 査読

    Yukihiro Watanabe, Shuhei Tara, Takuya Nishino, Katsuhito Kato, Yoshiaki Kubota, Daisuke Hayashi, Kosuke Mozawa, Junya Matsuda, Hideki Miyachi, Yukichi Tokita, Yu-ki Iwasaki, Masahiro Yasutake, Kuniya Asai

    International Heart Journal   65 ( 2 )   190 - 198   2024年3月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Heart Journal (Japanese Heart Journal)  

    DOI: 10.1536/ihj.23-596

    researchmap

  • Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure 査読

    Yukihiro Watanabe, Yoshiaki Kubota, Takuya Nishino, Shuhei Tara, Katsuhito Kato, Daisuke Hayashi, Junya Matsuda, Hideki Miyachi, Yukichi Tokita, Yu‐ki Iwasaki, Kuniya Asai

    ESC Heart Failure   2024年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Aims

    Fractional excretion of urea nitrogen (FEUN), used to differentiate the cause of acute kidney injury, has emerged as a useful fluid index in patients with heart failure (HF). We hypothesized that FEUN could be useful in identifying worsening renal function (WRF) associated with poor outcomes in patients with acute HF (AHF).

    Methods and results

    Overall, 1103 patients with AHF (median age, 78 years; male proportion, 60%) were categorized into six groups according to the presence of WRF and FEUN values (low, ≤32.1%; medium, &gt;32.1% and ≤38.0%; and high, &gt;38.0%) at discharge. WRF was defined as an increase of ≥0.3 mg/dL in the serum creatinine level from admission to discharge. FEUN was calculated by the following formula: (urinary urea × serum creatinine) × 100/(serum urea × urinary creatinine). The cut‐off values for low, medium, and high FEUN were based on a previous study. The primary outcome of this study was HF readmission after hospital discharge. During the 1 year follow‐up, 170 HF readmissions occurred. Kaplan–Meier analysis revealed significantly higher HF readmission rates in patients with WRF than in those without WRF (log‐rank test, P &lt; 0.001). Additionally, among patients with WRF, HF readmission rates were lowest in those with medium FEUN values, followed by those with low FEUN values and those with high FEUN values. On multivariable analysis, the presence of WRF with low or high FEUN values was independently associated with increased HF readmission, as compared with the absence of WRF with medium FEUN values. Notably, no association was noted between WRF with medium FEUN values and HF readmission.

    Conclusions

    The prognostic impact of WRF was significantly mediated by the FEUN values and was associated with worse outcomes only when the FEUN values were either low or high. Our study suggests that FEUN can identify prognostically relevant WRF in patients with AHF.

    DOI: 10.1002/ehf2.14755

    researchmap

  • Impact of hypoalbuminemia on in-hospital mortality in patients with takotsubo syndrome: A multicenter registry of the Tokyo cardiovascular care unit network 査読

    Yukihiro Watanabe, Tsutomu Yoshikawa, Toshiaki Isogai, Konomi Sakata, Tetsuo Yamaguchi, Kenshiro Arao, Yoshimitsu Takaoka, Taku Inohara, Yoichi Imori, Hiroki Mochizuki, Takeshi Yamamoto, Kuniya Asai, Ken Nagao, Morimasa Takayama

    Journal of Cardiology   2023年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.jjcc.2023.06.006

    researchmap

  • 貧血を有する心不全患者を対象とした赤血球輸血がその後の心血管イベントに及ぼす影響に関する検討 傾向スコアマッチング解析(Impact of Red Blood Cell Transfusion on Subsequent Cardiovascular Events in Heart Failure Patients with Anemia: A Propensity Score-matching Analysis)

    渡邉 将央, 太良 修平, 西野 拓也, 加藤 活人, 久保田 芳明, 林 太祐, 茂澤 幸右, 松田 淳也, 宮地 秀樹, 時田 祐吉, 八島 正明, 岩崎 雄樹, 安武 正弘, 清水 渉

    日本循環器学会学術集会抄録集   87回   OJ37 - 8   2023年3月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本循環器学会  

    researchmap

  • Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease. 査読 国際誌

    Yukihiro Watanabe, Yoshiaki Kubota, Takuya Nishino, Shuhei Tara, Katsuhito Kato, Daisuke Hayashi, Kosuke Mozawa, Junya Matsuda, Yukichi Tokita, Masahiro Yasutake, Kuniya Asai, Yu-Ki Iwasaki

    ESC heart failure   10 ( 3 )   1706 - 1716   2023年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIMS: Maintenance of euvolaemia with diuretics is critical in heart failure (HF) patients with chronic kidney disease (CKD); however, it is challenging because no reliable marker of volume status exists. Fractional excretion of urea nitrogen (FEUN) is a useful index of volume status in patients with renal failure. We aimed to examine whether FEUN is a surrogate marker of volume status for risk stratification in HF patients with CKD. METHODS AND RESULTS: We examined 516 HF patients with CKD (defined as discharge estimated glomerular filtration rate < 60 mL/min/1.73 m2 ) whose FEUN was measured at discharge (median age, 80 years; 58% male). The patients were divided into four groups according to quartile FEUN value at discharge: low-FEUN, FEUN ≤ 32.1; medium-FEUN, 32.1 < FEUN ≤ 38.0; high-FEUN, 38.0 < FEUN ≤ 43.7; and extremely-high-FEUN, FEUN > 43.7. FEUN was calculated by the following formula: (urinary urea × serum creatinine) × 100/(serum urea × urinary creatinine). During the 3 year follow-up, 131 HF readmissions occurred. Kaplan-Meier analysis showed that the HF readmission rate was significantly lower in the medium-FEUN group than in the other three groups (log-rank test, P = 0.029). Multivariate Cox regression analysis identified the low-FEUN, high-FEUN, and extremely-high-FEUN values as independent factors associated with post-discharge HF readmission. In the analysis of 130 patients who underwent right heart catheterization during hospitalization, a significant correlation between FEUN value and right atrial pressure was observed (R = 0.243, P = 0.005). Multivariate linear regression analysis revealed that FEUN value at discharge decreased in a dose-dependent manner with loop diuretics. CONCLUSIONS: In HF patients with CKD, FEUN is a potential marker of volume status for risk stratification of post-discharge HF readmission. Low FEUN value (FEUN ≤ 32.1) may represent intravascular dehydration, whereas high FEUN value (FEUN > 38.0) may represent residual congestion; both of them were independent risk factors for HF readmission. FEUN may be useful to determine euvolaemia and guide fluid management in HF patients with CKD.

    DOI: 10.1002/ehf2.14327

    PubMed

    researchmap

  • External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening - A Retrospective Cohort Study. 査読

    Yukihiro Watanabe, Hiroshige Murata, Hitoshi Takano, Tomonari Kiriyama, Shinobu Kunugi, Masato Hachisuka, Saori Uchiyama, Junya Matsuda, Hiroyuki Nakano, Yoichi Imori, Kenji Yodogawa, Yu-Ki Iwasaki, Eitaro Kodani, Akira Shimizu, Wataru Shimizu

    Circulation reports   4 ( 12 )   579 - 587   2022年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: The Kumamoto criteria have been proposed as a non-invasive screen for transthyretin amyloid cardiomyopathy. This study assessed the validity of the Kumamoto criteria externally. Methods and Results: The study included 138 patients (median age 73 years; 65% male) who underwent 99 mTc-pyrophosphate (PYP) scintigraphy. Patients were divided into 4 groups according to total scores on the Kumamoto criteria (i.e., 0-3) for the following 3 factors: high-sensitivity cardiac troponin T ≥0.0308 ng/mL, wide (≥120 ms) QRS, and left ventricular posterior wall thickness ≥13.6 mm. The diagnostic performance and positive predictive value (PPV) of the Kumamoto criteria for positive 99 mTc-PYP scintigraphy were validated. Eighteen (13%) patients were positive on 99 mTc-PYP scintigraphy. The Kumamoto criteria had a favorable diagnostic performance (area under the curve 0.808). The PPV for groups with scores of 0, 1, 2, and 3 was 0% (n=0/42), 11% (n=6/57), 21% (n=7/33), and 83% (n=5/6), respectively, which is lower, particularly for those with a score of 2, than in the original Kumamoto cohort. However, the PPV increased after combining the Kumamoto criteria with a history of orthopedic diseases (spinal canal stenosis and/or carpal tunnel syndrome). Conclusions: This study suggests that the Kumamoto criteria have a favorable diagnostic performance; however, the PPV may decrease depending on the study population. Combining the Kumamoto criteria with the presence of orthopedic disease may improve the PPV.

    DOI: 10.1253/circrep.CR-22-0110

    PubMed

    researchmap

  • Fatal pulmonary embolism caused by a giant popliteal vein aneurysm mimicking a ganglion cyst 査読 国際誌

    Yukihiro Watanabe, Yuhi Fujimoto, Yuji Maruyama, Wataru Shimizu

    European Heart Journal - Case Reports   6 ( 2 )   ytac088   2022年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    DOI: 10.1093/ehjcr/ytac088

    PubMed

    researchmap

    その他リンク: https://academic.oup.com/ehjcr/article-pdf/6/2/ytac088/42623200/ytac088.pdf

  • Impact of the COVID-19 Pandemic on ST-elevation Myocardial Infarction from a Single-center Experience in Tokyo 査読

    Yukihiro Watanabe, Hideki Miyachi, Kosuke Mozawa, Kenta Yamada, Eiichiro Oka, Reiko Shiomura, Yoichiro Sugizaki, Junya Matsuda, Jun Nakata, Shuhei Tara, Yukichi Tokita, Yu-ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Wataru Shimizu

    Internal Medicine   60 ( 23 )   3693 - 3700   2021年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Society of Internal Medicine  

    Objective The coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on global healthcare systems. Some studies have reported the negative impact of COVID-19 on ST-elevation myocardial infarction (STEMI) patients; however, the impact in Japan remains unclear. This study investigated the impact of the COVID-19 pandemic on STEMI patients admitted to an academic tertiary-care center in Tokyo, Japan. Methods In this retrospective, observational, cohort study, we included 398 consecutive patients who were admitted to our institute from January 1, 2018, to March 10, 2021, and compared the incidence of hospitalization, clinical characteristics, time course, management, and outcomes before and after March 11, 2020, the date when the World Health Organization declared COVID-19 a pandemic. Results There was a 10.7% reduction in hospitalization of STEMI patients during the COVID-19 pandemic compared with that in the previous year (117 vs. 131 cases). During the COVID-19 pandemic, the incidence of late presentation was significantly higher (26.5% vs. 12.1%, p<0.001), and the onset-to-door [241 (IQR: 70-926) vs. 128 (IQR: 66-493) minutes, p=0.028] and door-to-balloon [72 (IQR: 61-128) vs. 60 (IQR: 43-90) min, p<0.001] times were significantly longer than in the previous year. Furthermore, the in-hospital mortality was higher, but the difference was not significant (9.4% vs. 5.0%, p=0.098). Conclusion The COVID-19 pandemic significantly impacted STEMI patients in Tokyo and resulted in a slight decrease in hospitalization, a significant increase in late presentation and treatment delays, and a slight but nonsignificant increase in mortality. In the COVID-19 era, the acute management system for STEMI in Japan must be reviewed.

    DOI: 10.2169/internalmedicine.8220-21

    PubMed

    researchmap

  • Successful Prophylactic Endovascular Therapy for a Rapidly Expanding Hepatic Arterial Aneurysm in a Patient with Vascular Ehlers–Danlos Syndrome 査読

    Yukihiro Watanabe, Koichi Akutsu, Daisuke Yasui, Fumie Sugihara, Hideki Miyachi, Hiroshi Hayashi, Eiichiro Oka, Hidenori Komiyama, Shin-ichiro Kumita, Wataru Shimizu

    Annals of Vascular Diseases   14 ( 2 )   163 - 167   2021年6月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:The Editorial Committee of Annals of Vascular Diseases  

    Vascular Ehlers-Danlos syndrome (vEDS) causes fatal vascular complications due to vascular fragility. However, invasive therapeutic procedures are generally avoided except in emergencies. We report a case of vEDS presenting with rapid expansion of a hepatic arterial aneurysm successfully treated using prophylactic endovascular therapy. A 43-year-old woman with vEDS confirmed by genetic testing was hospitalized for a symptomatic hepatic arterial aneurysm that expanded rapidly within a week. Prophylactic coil embolization was then successfully performed. Although the general applicability of this approach cannot be determined, prophylactic endovascular therapy can clearly be an option for arterial aneurysms at high risk of rupture.

    DOI: 10.3400/avd.cr.20-00144

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • Medicina 内科医のための臨床問題集

    長門 直( 担当: 分担執筆)

    医学書院  2024年4月 

     詳細を見る

MISC

  • 経皮的冠動脈インターベンションの長期予後に対するSYNTAXスコアとSYNTAXスコアIIの変化の影響

    小野有希, 時田祐吉, 石原翔, 渡邉将央, 木村徳宏, 澁谷淳介, 塩村玲子, 松田淳也, 野間さつき, 久保田芳明, 中田淳, 宮地秀樹, 太良修平, 山本剛, 浅井邦也

    日本循環器学会学術集会(Web)   88th   2024年

     詳細を見る

  • 最適な退院処方日数を心不全チームで考える

    林太祐, 久保田芳明, 西野拓也, 完山穂波, 岩出佳樹, 橘貴大, 渡邉将央, 松田淳也, 加藤活人, 太良修平, 時田佑吉, 宮地秀樹, 伊勢雄也, 岩崎雄樹, 浅井邦也

    日本心不全学会学術集会プログラム・抄録集   27th (CD-ROM)   2023年

     詳細を見る

  • SYNTAX score,SYNTAX score IIの経時的変化と予後との関連

    中村有希, 時田祐吉, 石原翔, 渡邉将央, 木村徳宏, 澁谷淳介, 塩村玲子, 松田淳也, 野間さつき, 久保田芳明, 中田淳, 宮地秀樹, 太良修平, 山本剛, 浅井邦也

    日本心臓病学会学術集会(Web)   71st   2023年

     詳細を見る

  • 心不全患者へのピモベンダン導入によるGDMT強化は再入院率の低下に寄与するか?

    岩出佳樹, 久保田芳明, 林太祐, 西野拓也, 橘貴大, 渡邉将央, 松田淳也, 加藤活人, 太良修平, 宮地秀樹, 時田祐吉, 伊勢雄也, 岩崎雄樹, 浅井邦也

    日本心不全学会学術集会プログラム・抄録集   27th (CD-ROM)   2023年

     詳細を見る

  • 退院時看護必要度B項目が初発心不全患者の予後に与える影響

    完山穂波, 久保田芳明, 大金美羽子, 背戸陽子, 西野卓也, 林太祐, 岩出佳樹, 加藤活人, 渡邉将央, 松田淳也, 太良修平, 時田祐吉, 宮地秀樹, 岩崎雄樹, 浅井邦也

    日本心不全学会学術集会プログラム・抄録集   27th (CD-ROM)   2023年

     詳細を見る

  • 洞不全症候群による心不全を契機に診断したALアミロイドーシスの1例

    澤畠摩那, 渡邉将央, 新井俊貴, 林洋史, 久保田芳明, 太良修平, 岩崎雄樹, 浅井邦也

    日本内科学会関東支部関東地方会   684th   2023年

     詳細を見る

  • 心不全患者の左室駆出率によってピモベンダンの効果に差異はあるか?

    岩出佳樹, 林太祐, 久保田芳明, 西野拓也, 渡邉将央, 橘貴大, 松田淳也, 加藤活人, 太良修平, 宮地秀樹, 時田祐吉, 伊勢雄也, 岩崎雄樹, 浅井邦也

    日本医療薬学会年会講演要旨集(Web)   33rd   2023年

     詳細を見る

  • 心不全患者において退院処方日数と予約外受診は予後に影響を与えるか

    林太祐, 久保田芳明, 岩出佳樹, 西野拓也, 橘貴大, 渡邉将央, 松田淳也, 加藤活人, 太良修平, 時田祐吉, 宮地秀樹, 伊勢雄也, 岩崎雄樹, 浅井邦也

    日本医療薬学会年会講演要旨集(Web)   33rd   2023年

     詳細を見る

▼全件表示

講演・口頭発表等

  • 著明な低心機能を伴う心不全管理を長期に渡り管理しえた野生型ATTRアミロイドーシスの一例

    第656回日本内科学会関東地方会  2019年12月 

     詳細を見る

  • 急性大動脈解離を発症した巨細胞性動脈炎の一例

    第254回日本循環器学会関東甲信越地方会  2019年12月 

     詳細を見る

  • 心不全患者に対する赤血球輸血とその後の心血管イベントの検討

    渡邉 将央, 太良 修平, 西野 拓也, 加藤 活人, 久保田 芳明, 林 太祐, 茂澤 幸右, 松田 淳也, 時田 祐吉, 伊勢 雄也, 岩崎 雄樹, 安武 正弘, 清水 渉

    第70回日本心臓病学会学術集会  2022年9月 

     詳細を見る

  • 腎障害合併心不全患者の利尿剤管理における尿中尿素窒素排泄分画の有用性

    渡邉 将央, 久保田 芳明, 西野 拓也, 太良 修平, 加藤 活人, 林 太祐, 茂澤 幸右, 松田 淳也, 時田 祐吉, 伊勢 雄也, 岩崎 雄樹, 安武 正弘, 清水 渉

    第26回日本心不全学会学術集会  2022年10月 

     詳細を見る

  • トランスサイレチン型心アミロイドーシスの診断におけるKumamoto criteriaの有用性 Real-World Practice

    渡邉 将央, 村田 広茂, 高野 仁司, 蜂須賀 誠人, 内山 沙央里, 久保田 芳明, 井守 洋一, 宮地 秀樹, 太良 修平, 時田 祐吉, 淀川 顕司, 岩崎 雄樹, 功刀 しのぶ, 清水 渉

    第69回日本心臓病学会学術集会  2021年9月 

     詳細を見る

  • 本邦におけるCOVID-19パンデミックがST上昇型心筋梗塞患者に与える影響

    渡邉 将央, 宮地 秀樹, 茂澤 幸右, 山田 健太, 岡 英一郎, 塩村 玲子, 杉崎 陽一郎, 松田 淳也, 中田 淳, 山本 剛, 岩崎 雄樹, 高野 仁司, 清水 渉

    第69回日本心臓病学会学術集会  2021年9月 

     詳細を見る

  • 急速拡大した肝動脈瘤に対しカテーテル治療が成功した血管型Ehlers-Danlos症候群の1例

    第256回日本循環器学会関東甲信越地方会  2020年7月 

     詳細を見る

  • 非侵襲的検査法による心不全患者に潜む心アミロイドーシスの同定

    第85回日本循環器学会学術集会  2021年3月 

     詳細を見る

  • たこつぼ症候群患者における低アルブミン血症の院内死亡率への影響: 東京都CCUネットワークによる検討

    第87回日本循環器学会学術集会  2023年3月 

     詳細を見る

  • 貧血を合併した心不全患者に対する赤血球輸血がその後の心血管イベントに与える影響:傾向スコアマッチング解析

    第87回日本循環器学会学術集会  2023年3月 

     詳細を見る

  • 尿中尿素窒素排泄分画は心不全患者の予後悪化に寄与する腎機能悪化を識別する

    渡邉 将央, 久保田 芳明, 西野 拓也, 太良 修平, 加藤 活人, 林 太祐, 橘 貴大, 岩出 佳樹, 松田 淳也, 宮地 秀樹, 時田 祐吉, 岩崎 雄樹, 淺井邦也

    第27回日本心不全学会学術集会  2023年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Fractional excretion of urea nitrogen can identify true worsening renal function in patients with acute heart failure

    Yukihiro Watanabe, Yoshiaki Kubota, Takuya Nishino, Shuhei Tara, Katsuhito Kato, Daisuke Hayashi, Takahiro Tachibana, Kosuke Mozawa, Junya Matsuda, Hideki Miyachi, Yukichi Tokita, Yu-ki Iwasaki, Masahiro Yasutake, Kuniya Asai

    European Society of Cardiology Congress 2023  2023年8月 

     詳細を見る

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • 第18回ダイバーシティ・フォーラム/循環器専門医試験対策セミナー 番外編

    第271回日本循環器学会関東甲信越地方会  2024年2月 

     詳細を見る

  • Heart Failure Therapies: An Asian Perspective

    Daniel Wang, MD, Chern-en Chiang, MD, PhD, Yukihiro Watanabe, MD, Junho Hyun, MD

    JACC: Asia Pulse  2024年1月 

     詳細を見る

  • たこつぼ症候群に、糖尿病パラドックスは存在するか?

    渡邉 将央, 吉川 勉, 荒尾 憲司郎, 磯貝 俊明, 江頭 徹, 井守 洋一, 望月 宏樹, 山本 剛, 淺井 邦也, 香坂 俊, 高山 守正

    第10回日本心筋症研究会  2024年5月 

     詳細を見る

▼全件表示

受賞

  • Young Investigator’s Award 最優秀賞

    2023年10月   第27回日本心不全学会学術集会  

     詳細を見る

  • 優秀演題賞

    2022年10月   第26回日本心不全学会学術集会  

     詳細を見る

  • Case Report Award 優秀賞

    2020年7月   第256回日本循環器学会関東甲信越地方会  

     詳細を見る